News summary

Biotech

Source: PR Newswire • Published: 16 Nov 2026, 23:34

Summarized by Masters of Longevity from PR Newswire.

A Phase 3 bladder cancer trial succeeded while a lung BLA was rejected and a Phase 2 dermatology trial failed.

Biotech
Key Takeaways
  • Cretostimogene trial was reported to reduce recurrence risk by 68%.
  • FDA rejected the lung cancer BLA due to no OS statistical improvement.
  • The anti-TSLP antibody trial failed despite clear target engagement.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.